Publications by authors named "Matthew Wintle"

Claim this Profile
A
Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
John B Buse, Jenny Han, Stephan Miller, Leigh MacConell, Richard Pencek, Matthew Wintle

Curr Med Res Opin· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.
Julia A Gaebler, Gerardo Soto-Campos, Peter Alperin, Marc Cohen, Amy Blickensderfer, Matthew Wintle

Vasc Health Risk Manag· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
Richard M Bergenstal, Louis P Garrison, Matthew Wintle, Amy Blickensderfer, Rolin Wade

Curr Med Res Opin· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.
Rosalind Fabunmi, Loretta L Nielsen, Ralph Quimbo, Brock Schroeder, Derek Misurski, Matthew Wintle

Curr Med Res Opin· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.
Michael E Minshall, Alan K Oglesby, Matthew E Wintle, William J Valentine, Stéphane Roze

Value Health· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
David C Klonoff, John B Buse, Loretta L Nielsen, Xuesong Guan, Christopher L Bowlus, Matthew E Wintle

Curr Med Res Opin· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.
Andrew P Yu, Eric Q Wu, Howard G Birnbaum, Srinivas Emani, Madeleine Fay, Matthew Wintle

Curr Med Res Opin· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Patric Nelson, Terri Poon, Xuesong Guan, Catherine Schnabel, Matthew Wintle

Diabetes Technol Ther· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes.
Catherine A Schnabel, Matthew Wintle, Orville Kolterman

Vasc Health Risk Manag· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
John B Buse, David C Klonoff, Loretta L Nielsen, Xuesong Guan, Christopher L Bowlus, Matthew E Wintle

Clin Ther· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects.
Erich Blase, Kristin Taylor, Hong-Ye Gao, Matthew Wintle, Mark Fineman

J Clin Pharmacol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4).
Federico Calara, Kristin Taylor, Jenny Han, Evelyn Zabala, Eh Moo Carr, Matthew Wintle

Clin Ther· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis